Ionis Pharmaceuticals Inc (NAS:IONS)
$ 35.91 -0.42 (-1.16%) Market Cap: 5.74 Bil Enterprise Value: 4.73 Bil PE Ratio: 0 PB Ratio: 8.65 GF Score: 40/100

Ionis Pharmaceuticals Inc at Piper Sandler Healthcare Conference Transcript

Nov 29, 2022 / 03:00PM GMT
Release Date Price: $38.76 (-3.89%)
Guyn Kim
Piper Sandler & Co., Research Division - Senior Research Analyst

All right. Good morning. Thank you, everyone, for joining us for our next company presentation. We have with us Ionis, and it's my pleasure to welcome CEO, Brett Monia. Thank you, Brett, for being here.

And just to start us off, a quick company overview and maybe to lead you a little bit. Ionis has a long history of being a leading antisense company. But could you go over the evolution of where you are now in the Phase III program, Phase III assets, the validation of the therapeutic targets and the LICA technology.

Brett P. Monia
Ionis Pharmaceuticals, Inc. - Founder, CEO & Director

Sure. Thank you, Do. It's a pleasure to be here. Great to talk about Ionis. So Ionis, of course, for those that are familiar with us, we're the pioneer in the field we now refer to as RNA therapeutics -- RNA targeted therapeutics, using originally antisense -- the antisense platform to go after undruggable targets and develop the platform. And now we've expanded into RNAi in addition to ASO

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot